Prapchompoothaweep remedy

Phase 2Small molecule

TThammasat University

Prapchompoothaweep remedy is one of 37 small molecule programs targeting Adverse Effect. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Adverse EffectActive, not recruiting

Adverse EffectPhase 2

Active, not recruiting

Competition

Competitive Landscape

47 competitors in Adverse Effect

#DrugCompanyPhaseTrials

Arcoxia

Novartis

Approved

1 2

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 3

Indocin

LLife Extension Foundation Inc.

Approved

1 4

Oxycontin

PProtega

Approved

1 5

Eldepryl

QQuagen

Approved

1 6

MS Contin

HHikma Pharmaceuticals LLC

Approved

1 7

Pulmicort

SSalix

Approved

1 8

Truvada

Gilead

Approved

1 9

Salbutamol

GSK

Approved

1 10

Salmeterol Fluticasone

AstraZeneca

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Adverse Effect1 trial

Efficacy and Adverse Effects of Prapchompoothaweep Remedy and Loratadine for Treatment in AR Patients

Completed·TThammasat University·Phase 2·NCT03640273·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Prapchompoothaweep remedy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Prapchompoothaweep remedy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Prapchompoothaweep remedy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Thammasat University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TThammasat University

Prapchompoothaweep remedy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Adverse Effect1 trial

References

Drug Info

Quick Facts

Related News